Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer [clinicaltrials:NCT00006370]
Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer [clinicaltrials:NCT00006370]
Bio2RDF identifier
NCT00006370
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00006370
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Radiolabeled ...... or metastatic breast cancer.
brief title [clinicaltrials_vocabulary:brief-title]
Radiolabeled SMT-487 (Yttrium ...... er or Metastatic Breast Cancer
completion date [clinicaltrials_vocabulary:completion-date]
2004-06-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... ll be accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-10-04T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
male breast cancer
recurrent breast cancer
recurrent small cell lung cancer
stage IV breast cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-04-30T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00006370
official title [clinicaltrials_vocabulary:official-title]
A Phase II, Open-label, Multi- ...... ned by OctreoScan Scintigraphy
org study id [clinicaltrials_vocabulary:org-study-id]
NOVARTIS-CSMT-487A0103
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-06-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2000-07-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-04-01T00:00:00Z
identifier
clinicaltrials:NCT00006370
title
Radiolabeled SMT-487 (Yttrium ...... er or Metastatic Breast Cancer
@en
type
label
Radiolabeled SMT-487 (Yttrium ...... r [clinicaltrials:NCT00006370]
@en